Challenges and options in the etiotropic treatment of bacterial rhinosinusitis

Abstract

Rhinosinusitis is one of the most common human nosologies, which doctors of different specialties encounter in inpatient and outpatinet practice. According to statistics, every year in the United States up to 31 million people get sick with rhinosinusitis; in Russia, the figure is slightly lower - up to 10 million clinical cases, which is probably due to the lower number of patients seeking medical aid. In Europe, different forms of rhinosinusitis affect 5--15% of the adult population, while among children inflammation of the paranasal sinuses occurs in 21% of the population. [1-4]. Rhinosinusitis results in heavy economic burdens and financial costs associated with the diagnosis and treatment of the pathological process and temporary disability.

Keywords

• риносинуситы
• антибактериальная терапия
• фторхинолоны
• левофлоксацин
• rhinosinusitis
• antibiotic therapy
• fluoroquinolones
• levofloxacin